FDA To Review Qualified Health Claim For Xangold

Cognis Nutrition & Health, LaGrange, IL, has petitioned FDA for a qualified health claim (QHC) linking consumption of Xangold® natural lutein esters to a reduced risk of two major eye diseases: age-related macular degeneration and cataracts. FDA has slated the QHC (2004Q-0180) for review and is expected to respond to Cognis’ petition within eight months. The proposed petition states: “Consumption of 12 mg Xangold lutein esters per day may reduce the risk of age-related macular degeneration (AMD) and cataract formation. FDA has determined that the evidence is supportive, but not conclusive, for this claim. (This food/dietary supplement provides _ mg lutein esters per serving).”